Anzeige
Mehr »
Mittwoch, 24.09.2025 - Börsentäglich über 12.000 News
Avanti Gold explodiert auf neue Hochs: Gold bei 3.750 $ - und Misisi zündet die nächste Stufe!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
717 Leser
Artikel bewerten:
(2)

Gamma Biosciences: Univercells Technologies Acquired by Donaldson Company

MENLO PARK, Calif., June 30, 2023 /PRNewswire/ -- Gamma Biosciences, a life sciences platform created by global investment firm KKR to address the advanced therapy bioprocessing market, today announced that its operating company, Univercells Technologies ("UT"), a leading provider of novel biomanufacturing technologies for flexible and scalable advanced therapies and vaccine production, has been acquired by Donaldson Company, Inc. (NYSE: DCI).


Donaldson is a leading worldwide provider of innovative filtration products and solutions. The deal follows several recent acquisitions by Donaldson in the field of bioprocessing, including Solaris Biotechnology, Purilogics and Isolere Bio. UT's single-use bioreactor systems and integrated biomanufacturing platforms, focused on the production of viruses used in cell and gene therapy, viral vaccines and other therapeutics, will add to Donaldson's growing offering in life sciences.

"I am proud of the achievements of our team during this journey with Univercells and Gamma Biosciences, as we ramped-up our development, production and service capabilities and continued to innovate and launch novel products," said Mathias Garny, CEO of UT. "We are now looking forward to this new era with Donaldson to further strengthen our market position and deliver robust, end-to-end biomanufacturing solutions to our customers as they advance towards commercialization of advanced therapies and vaccines."

"We are delighted that UT will join Donaldson as it expands its presence in biomanufacturing, leveraging its legacy of filtration technology leadership" said Matt Gunnison, CEO of Gamma Biosciences. "UT has developed a best-in-class platform for efficient manufacturing of gene therapies and vaccines and will be well positioned as part of the larger Donaldson organization to support the market going forward."

Gamma Biosciences first invested in UT in June 2020 and has worked closely with the company to fund the development, manufacture and commercialization of the scale-X and NevoLine product lines, which are based on the company's novel structured, fixed-bed design for high-density adherent and suspension cell culture.

According to the terms of the transaction, Donaldson acquired all outstanding shares of the business from Gamma and its fellow shareholder, Univercells SA, for approximately €136M in cash net of debt. Rothschild & Co acted as financial advisor to Univercells Technologies. Sidley Austin LLP and Freshfields Bruckhaus Deringer US LLP acted as legal advisors to Gamma and Univercells, respectively.

About Gamma Biosciences
Gamma Biosciences is a life sciences tools platform created by KKR. Gamma's mission is to support leading players in next-generation bioprocessing for advanced therapies by acquiring or investing in high-potential businesses with outstanding technology and accelerating their growth.

About Donaldson Company, Inc.
Founded in 1915, Donaldson (NYSE: DCI) is a global leader in technology-led filtration products and solutions, serving a broad range of industries and advanced markets. Our diverse, skilled employees at over 140 locations on six continents partner with customers-from small business owners to the world's biggest OEM brands-to solve complex filtration challenges. Discover how Donaldson is Advancing Filtration for a Cleaner World at www.Donaldson.com.

About Univercells Technologies
Univercells Technologies is a global provider of innovative biomanufacturing technologies to achieve cost-effective advanced therapies and vaccines production from R&D to commercial scales. The Company offers a comprehensive technology portfolio leveraging the strengths of process intensification and chaining as a direct answer to the growing demand of viral vectors and viral vaccines. Univercells Technologies is committed to helping customers increase performance with minimized footprint and costs today, while anticipating the needs of tomorrow.

Logo - https://mma.prnewswire.com/media/1295160/Gamma__Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/univercells-technologies-acquired-by-donaldson-company-301867767.html

© 2023 PR Newswire
Solarbranche vor dem Mega-Comeback?
Lange galten Solaraktien als Liebling der Börse, dann kam der herbe Absturz: Zinsschock, Überkapazitäten aus China und ein Preisverfall, der selbst Marktführer wie SMA Solar, Enphase Energy oder SolarEdge massiv unter Druck setzte. Viele Anleger haben der Branche längst den Rücken gekehrt.

Doch genau das könnte jetzt die Chance sein!
Die Kombination aus KI-Explosion und Energiewende bringt die Branche zurück ins Rampenlicht:
  • Rechenzentren verschlingen Megawatt – Solarstrom bietet den günstigsten Preis je Kilowattstunde
  • Moderne Module liefern Wirkungsgrade wie Atomkraftwerke
  • hina bremst Preisdumping & pusht massiv den Ausbau
Gleichzeitig locken viele Solar-Aktien mit historischen Tiefstständen und massiven Short-Quoten, ein perfekter Nährboden für Kursrebound und Squeeze-Rally.

In unserem exklusiven Gratis-Report zeigen wir dir, welche 4 Solar-Aktien besonders vom Comeback profitieren dürften und warum jetzt der perfekte Zeitpunkt für einen Einstieg sein könnte.

Laden Sie jetzt den Spezialreport kostenlos herunter, bevor die Erholung am Markt beginnt!

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.